274 related articles for article (PubMed ID: 16359313)
1. Domains of group A streptococcal M protein that confer resistance to phagocytosis, opsonization and protection: implications for vaccine development.
McArthur JD; Walker MJ
Mol Microbiol; 2006 Jan; 59(1):1-4. PubMed ID: 16359313
[TBL] [Abstract][Full Text] [Related]
2. Binding of human plasma proteins to Streptococcus pyogenes M protein determines the location of opsonic and non-opsonic epitopes.
Sandin C; Carlsson F; Lindahl G
Mol Microbiol; 2006 Jan; 59(1):20-30. PubMed ID: 16359315
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
[TBL] [Abstract][Full Text] [Related]
4. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
[TBL] [Abstract][Full Text] [Related]
5. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
6. Variable susceptibility to opsonophagocytosis of group A streptococcus M-1 strains by human immune sera.
Villaseñor-Sierra A; McShan WM; Salmi D; Kaplan EL; Johnson DR; Stevens DL
J Infect Dis; 1999 Dec; 180(6):1921-8. PubMed ID: 10558949
[TBL] [Abstract][Full Text] [Related]
7. Host-pathogen interactions in Streptococcus pyogenes infections, with special reference to puerperal fever and a comment on vaccine development.
Areschoug T; Carlsson F; Stålhammar-Carlemalm M; Lindahl G
Vaccine; 2004 Dec; 22 Suppl 1():S9-S14. PubMed ID: 15576204
[TBL] [Abstract][Full Text] [Related]
8. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
[TBL] [Abstract][Full Text] [Related]
9. The streptococcal M protein: a highly versatile molecule.
Smeesters PR; McMillan DJ; Sriprakash KS
Trends Microbiol; 2010 Jun; 18(6):275-82. PubMed ID: 20347595
[TBL] [Abstract][Full Text] [Related]
10. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS.
Smeesters PR; Dramaix M; Van Melderen L
Vaccine; 2010 Jan; 28(4):883-5. PubMed ID: 19963033
[No Abstract] [Full Text] [Related]
11. Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development.
Smeesters PR; Mardulyn P; Vergison A; Leplae R; Van Melderen L
Vaccine; 2008 Oct; 26(46):5835-42. PubMed ID: 18789365
[TBL] [Abstract][Full Text] [Related]
12. Anti-phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M-related protein.
Courtney HS; Hasty DL; Dale JB
Mol Microbiol; 2006 Feb; 59(3):936-47. PubMed ID: 16420362
[TBL] [Abstract][Full Text] [Related]
13. Prospects for a group A streptococcal vaccine.
McMillan DJ; Chhatwal GS
Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
[TBL] [Abstract][Full Text] [Related]
15. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
17. Group A streptococcal vaccines: facts versus fantasy.
Steer AC; Batzloff MR; Mulholland K; Carapetis JR
Curr Opin Infect Dis; 2009 Dec; 22(6):544-52. PubMed ID: 19797947
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
Bauer MJ; Georgousakis MM; Vu T; Henningham A; Hofmann A; Rettel M; Hafner LM; Sriprakash KS; McMillan DJ
Vaccine; 2012 Mar; 30(12):2197-205. PubMed ID: 22265945
[TBL] [Abstract][Full Text] [Related]
19. Identification and assessment of new vaccine candidates for group A streptococcal infections.
McMillan DJ; Batzloff MR; Browning CL; Davies MR; Good MF; Sriprakash KS; Janulczyk R; Rasmussen M
Vaccine; 2004 Jul; 22(21-22):2783-90. PubMed ID: 15246612
[TBL] [Abstract][Full Text] [Related]
20. Evasion of phagocytosis through cooperation between two ligand-binding regions in Streptococcus pyogenes M protein.
Carlsson F; Berggård K; Stålhammar-Carlemalm M; Lindahl G
J Exp Med; 2003 Oct; 198(7):1057-68. PubMed ID: 14517274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]